In short
Rubbish Talk rates the Daily Mail's claim that Novo "sheds 13,000 jobs" a 2/10 because the figure, split between 9,000 announced layoffs and 4,000 unreplaced departures, matches what Novo itself disclosed and what rival outlets reported the same day.
The Verdict
Base fact, lightly dressed up. The 13,000 number, the split between cuts and attrition, and the competitive "war" framing against Eli Lilly all check out against the company's own presentation and same-day reporting elsewhere. The only stretch is the pun-heavy "slims down" framing, which is colourful rather than misleading given the story is genuinely about cost-cutting.
What actually happened
Novo, maker of Wegovy and Ozempic, told investors on 21 September that it has shed 13,000 jobs over the past year: 9,000 through direct cuts and 4,000 more through natural attrition. The update came alongside CEO Mike Doustdar's turnaround plan, as the company falls behind Eli Lilly's Mounjaro and Zepbound in the weight-loss drug market.
Key facts
- 13,000 total jobs shed: 9,000 cut directly, plus 4,000 who left and were not replaced, as stated in the article and corroborated by same-day reporting of the figure elsewhere.
- Shares fell in early trading on the update, 9 per cent per the Mail; a same-day report from another outlet put the intraday fall at as much as 7 per cent, a normal spread for fast-moving market reporting.
- Stock down more than 70 per cent from its mid-2024 peak, per the article.
- Doustdar's targets: Novo has announced a sweeping restructuring plan that will see 9,000 jobs eliminated worldwide by the end of 2026, representing roughly 11% of its global headcount, consistent with the Mail's 9,000 figure.
- Novo aims for more than five new blockbuster drugs by 2030, £17bn in 2035 sales, and 60 million patients reached by 2030, per the company presentation as reported.
What to watch for
Watch whether the 9,000-job cut, first announced earlier in 2026 as a separate restructuring, gets folded into future "13,000" tallies without clarifying it spans two announcements rather than one fresh cut. Also watch semaglutide's patent cliff in the early 2030s, flagged in the article as the real long-term threat behind today's cost-cutting headline.
